ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2336

Patients with Psoriasis with a Positive Psoriasis Epidemiology Screening Tool (PEST): Similarities and Differences Compared to PsA and Patients with Psoriasis and a Negative PEST
Abstract Number: 2337

Patient Characteristics and Outcomes of Emergency Visits in Psoriatic Arthritis: Results from the U.S. Nationwide Emergency Department Sample (NEDS)
Abstract Number: 2338

TNF Inhibitor Therapy Increases Absolute Lymphocyte Count Which Is Associated with Lower Mortality in Patients with Psoriatic Arthritis
Abstract Number: 2339

Increased Risk of Psoriatic Arthritis in Patients with Familial Mediterranean Fever: A Population-Based Cohort Study
Abstract Number: 2340

Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis: Diagnosis Rates, Referral Pathways, and Educational Value of Screening
Abstract Number: 2341

Influence of Patient Baseline Characteristics on Zasocitinib (TAK-279) Efficacy, a Selective Oral Tyrosine Kinase 2 Inhibitor: A Randomized Phase 2b Trial in Psoriatic Arthritis
Abstract Number: 2342

Guselkumab Shows Similar Domain-Specific Efficacy in Females and Males with Active Psoriatic Arthritis: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Abstract Number: 2343

Temporal Trends in and Associations with NSAID Prescription in Adult and Pediatric Patients with IBD
Abstract Number: 2344

Secukinumab Retention and Effectiveness in Patients with Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: 5-year Final Results of a Prospective Real-world Study
Abstract Number: 2345

Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis
Abstract Number: 2346

Treatment Effect on Predictors of Ankylosis in Axial Spondyloarthritis
Abstract Number: 2347

Drug Survival in Spondyloarthritis: Anti-IL17 Outperforms Anti-TNF in First Biologic Treatment
Abstract Number: 2348

Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension
Abstract Number: 2349

Predictive Potential of Serum Metabolites Associated with Treatment Response to Interleukin -17 Inhibitors in Patients with PsA
Abstract Number: 2350

Do Smoking and Obesity Impact Secukinumab Treatment Outcomes? Real-world Data from 1,202 European Patients with Psoriatic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].